NIAGEN BIOSCIENCE INC (NAGE)
Consumer Staples · NAD+ precursors and healthy aging supplements · NASDAQ
A global bioscience company commercializing nicotinamide riboside (Niagen®), a NAD+ precursor, through consumer supplements, pharmaceutical-grade ingredient supply, and clinical research collaborations targeting healthy aging.
What NIAGEN BIOSCIENCE INC does
Niagen Bioscience is a global bioscience company dedicated to promoting healthy aging through research, development, and commercialization of NAD+ precursors, primarily nicotinamide riboside chloride (NRC). The company operates across three business segments: (1) consumer products including Tru Niagen® dietary supplements and topical skincare products sold directly to consumers and through distributors; (2) ingredient supply of food-grade and pharmaceutical-grade Niagen® to manufacturers, 503B outsourcing facilities, and compounding pharmacies; and (3) pharmaceutical development with clinical research collaborations and Niagen Plus pharmaceutical-grade products for intravenous and injectable formulations. The company has established over 300 research collaborations with leading universities and research institutions to advance NAD+ science.
Themes: NAD+ biology and healthy aging, Dietary supplements, Pharmaceutical ingredients and compounding, Cellular metabolism and longevity, Consumer wellness products, Clinical research and medical foods
Fundamentals
- Price$3.21 as of 2026-08-21 close
- Market cap$254M as of 2026-08-21
- 1-year return-67.1% 2025-08-21 close $9.77 → 2026-08-21 close $3.21
- P/E14.92 as of 2026-08-24
- Net margin+12.4% as of 2026-08-24
- Gross margin+64.2% as of 2026-08-24
- ROE+20.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+11.0% as of 2026-08-24
- Revenue CAGR (3y)+21.6% SEC XBRL
- Beta2.03 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How NAGE compares in its sector
- price-to-earnings ratiobottom 25% 97 covered Consumer Staples peers, as of 2026-08-24
- net profit margintop 25% 116 covered Consumer Staples peers, as of 2026-08-24
- operating marginmiddle range 116 covered Consumer Staples peers, as of 2026-08-24
- gross margintop 10% 116 covered Consumer Staples peers, as of 2026-08-24
- return on equitymiddle range 116 covered Consumer Staples peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 109 covered Consumer Staples peers
Position among covered Consumer Staples companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NIAGEN BIOSCIENCE INC looks technically
NIAGEN BIOSCIENCE INC (NAGE) is trading 36.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 194 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 13 trading days ago. It is 71.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 36.3% below its 200-day average, the long-term trend line — a long-term downtrend | -36.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.30 | $3.30 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.04 | $5.04 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 2.87. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 194 trading days ago — a "death cross", a bearish long-term signal | 194 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 18.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 49.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($2.87 to $3.63) — its "stochastic" reading is 45 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 44.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.29 | $11.29 |
|---|---|---|
| From the 52-week high | it is 71.6% below its 52-week high (its highest price of the past year) | -71.6% |
| Above the 52-week low | it is 11.8% above its 52-week low (its lowest price of the past year) | +11.8% |
| Below the 52-week high | it is 71.6% below its highest point of the past year | 71.6% |
| Since a 20-day breakout | it made a new 20-day low about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day low about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $23.66 (set on 2021-02-25) | $23.66 |
| Given back of the 52-week move | over the past year its closes ranged ($2.96 to $10.26), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.47 to $7.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.4% |
| From the all-time high | it is 86.4% below its all-time high | -86.4% |
| Nearest price level | it is trading 13.1% below a resistance level at $3.63 — a price it turned at three times since 2024-10-14, most recently on 2026-08-04. Since 2024-08-21 it has 0 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +13.1% |
| All-time low | its lowest closing price on record is $0.33 (set on 2009-08-03) | $0.33 |
| Above the all-time low | it is 872.7% above its all-time low | +872.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 60th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1438 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1438 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.86 and $3.48 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.86 – $3.17 – $3.48 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 12.7 daily ranges below its 200-day average price (36.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.52× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Open gap | it gapped 10.7% below the previous close 12 sessions ago and has not traded back through the level it left behind at 3.47 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.7% |
| Gap filled | a 2.9% gap up opened on 2026-08-03 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.4 percentage points (the stock lost 8.0% while the market gained 2.3%) | -10.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 18.4 percentage points (the stock lost 15.3% while the market gained 3.1%) | -18.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 45.0 percentage points (the stock lost 34.0% while the market gained 11.1%) | -45.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 87.6 percentage points (the stock lost 67.1% while the market gained 20.5%) | -87.6% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 22.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -6.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 29% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.54 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -29.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $3.11 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +3.4% |
Price levels it has turned at before
NAGE last closed at $3.21 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 12 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.63 | Resistance | 13.1% above the last close | turned there three times · 2024-10-14 to 2026-08-04 |
| $4.73 | Resistance | 47.4% above the last close | turned there twice · 2026-02-23 to 2026-03-03 |
| $5.16 | Resistance | 60.9% above the last close | turned there three times · 2024-12-24 to 2026-05-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $2.87.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$12.08 range $8.50 – $22.00; median $10.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NAGE
- Consensus EPS estimate-$0.01 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the continued scientific validation and regulatory acceptance of NAD+ precursors like Niagen.","Vulnerability to competition from other NAD+ supplement providers and manufacturers of alternative healthy aging products.","Dependence on a portfolio of intellectual property and patents to protect proprietary ingredients."]
What changed in the latest 10-Q
AI-assisted comparison of NAGE's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference year changed from 2024 to 2025 in Annual Report citation (newer: December 31, 2025, filed March 4, 2026; older: December 31, 2024, filed March 4, 2025)
- Comparison period changed from three and nine months ended September 30, 2025 vs. 2024 to three months ended March 31, 2026 vs. 2025
- New 'Recent Developments' section added: Disposal of Analytical Reference Standards and Services Segment, completed February 2026 for ~$6.0 million with ~$4.8 million gain recognized
- Statement that analytical reference standards and services revenue is no longer included in ongoing operating results following closing date
- Removed:
- Detailed company history narrative removed (e.g., '2013 commercialized food-grade Niagen®', '2017 launched Tru Niagen®', '2024 launched Niagen Plus')
- References to specific regulatory approvals and jurisdictions removed (Health Canada, European Commission, Turkish Ministry of Agriculture, ANVISA, FSANZ)
- Statement about NAD+ decline 'by up to 65% between ages 30 and 70'
- List of disease areas studied changed from 'Alzheimer's disease, Parkinson's disease' to 'Ataxia-Telangiectasia, neurodegenerative diseases'
- Reference to 'more than 300 research collaborations' and specific institution names (NIH, Cornell, Dartmouth, Harvard, MIT, Cambridge, Mayo Clinic, Chiba, Sun Yat-sen) removed
- References to Scientific Advisory Board and specific advisors (Roger Kornberg, Charles Brenner) removed
- Previous 'Recent Developments' section content removed: Employee Stock Purchase Plan (June 24, 2025) and Purchase Commitments (Grace Supply Agreement, July 25, 2025)
- Reworded:
- Company description shifted from 'Our team, which includes world-renowned scientists, is pioneering research' to 'Our operations are centered on the research, development and commercialization' (more operational focus)
- NAD+ description expanded from basic definition to include 'may also be impacted by lifestyle and certain disease states' (removed specific percentage decline reference)
- Changed from 'novel form of vitamin B3' descriptor to direct reference as NAD+ precursor without vitamin B3 characterization
- Business platform description restructured: removed narrative history; added formal three-pillar structure (Consumer Products, Ingredients, Pharmaceutical Development)
- Pharmaceutical development section newly added as distinct business segment with statement 'we do not currently generate revenue from these activities'
- Reorganized and simplified regulatory approvals language; removed medical foods and FSANZ references
- Notes:
- The newer filing text appears truncated at 'In add' at end of Recent Developments section, preventing full assessment of content that may follow
- Comparison is between Q3 2025 filing (9/30/2025 data) and Q1 2026 filing (3/31/2026 data), representing different fiscal periods within different years
Risk Factors
- Added:
- Added risk factor bullet point: 'We are subject to potential payment processing risk.' under Risks Related to our Products section (filed 2026-05-06)
- Added risk factor bullet point: 'Compliance with stringent and changing global privacy and data security laws and regulations may increase our operating costs, expose us to liability, and restrict our ability to collect, use, transfer, and otherwise process data critical to our business. Any actual or perceived failure to comply could materially adversely affect our business, financial condition, or operations.' under Risks Related to Regulatory Approval section (filed 2026-05-06)
- Removed:
- Removed risk factor bullet point: 'We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.' from the beginning of Risks Related to our Company and Business list in summary section (filed 2025-11-04 version had this first)
- Reworded:
- Reordered risk factors in the summary section under 'Risks Related to our Company and Business:' - the capital requirements/financing risk was moved from first position to last position (filed 2026-05-06 vs filed 2025-11-04)
- Cyber security risk factor wording changed from 'Our business could be negatively impacted by cyber security incidents or threats, including without limitation a material interruption to our operations and our IT systems, a material interruption to our clinical trials, harm to our reputation, significant fines, penalties, litigation, and liabilities, regulatory investigations or lawsuits, including class actions, breach or triggering of data protection laws, privacy policies and data protection obligations, or a loss of revenue, customers or sales.' to 'Our business could be negatively impacted by cyber security incidents or threats, which could lead to data breaches, material interruption to our operations, manufacturing or laboratory systems, clinical trials, and IT systems, and violations of statutory and contractual privacy, confidentiality and data security obligations. This could result in significant fines, penalties, litigation, and liabilities, regulatory investigations or lawsuits, including class actions, reputational harm, and loss of revenue, customers or sales.' (filed 2026-05-06)
- Privacy/data security compliance risk factor wording significantly revised from 'Compliance with stringent and changing global privacy and data security laws and regulations could result in additional costs and liabilities to us or inhibit our ability to collect and, if applicable, process data globally, and the failure or perceived failure to comply with such laws and regulations could have a material adverse effect on our business, financial condition or results of operations.' to new version emphasizing increased operating costs, exposure to liability, and data processing restrictions (filed 2026-05-06)
- Changed 'Environmental, social and governance matters may impact our business and reputation.' to 'Environmental, social and governance matters and any related reporting obligations may impact our business and reputation.' - added reference to reporting obligations (filed 2026-05-06)
- Notes:
- The newer filing text is truncated at the end of the detailed risk factor section, so only the summary section and initial detailed risk factors can be fully compared
- The older filing text is also truncated, so complete comparison of all detailed risk factors is not possible
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for NAGE — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NAGE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,984,833
- Reported value $30,803,116
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NAGE had 4,545,665 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NAGE had 5.74% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.24 days to cover at the same settlement.
- Reported short interest (shares) 4,545,665
- Short interest (% of shares outstanding) 5.74%
- Prior settlement (shares) 4,786,324
- Reported change -5.03%
- Days to cover (reported) 7.24
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Elysium Health (private, produces NAD+ precursor basis point)
- Apeiron Therapeutics (NAD+ biologics)
- Replicel Life Sciences (cellular aging)
- Calico Labs (longevity research)
- GlycoMimetics (rare disease therapeutics)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does NIAGEN BIOSCIENCE INC (NAGE) do?
Niagen Bioscience is a global bioscience company dedicated to promoting healthy aging through research, development, and commercialization of NAD+ precursors, primarily nicotinamide riboside chloride (NRC). The company operates across three business segments: (1) consumer products including Tru Niagen® dietary supplements and topical skincare products sold directly to consumers and through distributors;
What sector is NIAGEN BIOSCIENCE INC (NAGE) in?
NIAGEN BIOSCIENCE INC (NAGE) is classified in the Consumer Staples sector. Its industry is NAD+ precursors and healthy aging supplements. It trades on NASDAQ.
Who are NIAGEN BIOSCIENCE INC's (NAGE) competitors?
Notable peers of NIAGEN BIOSCIENCE INC (NAGE) include Elysium Health (private, produces NAD+ precursor basis point), Apeiron Therapeutics (NAD+ biologics), Replicel Life Sciences (cellular aging), Calico Labs (longevity research) and GlycoMimetics (rare disease therapeutics). This peer set is informational only — not financial advice.
Is NIAGEN BIOSCIENCE INC (NAGE) overbought or oversold right now?
NIAGEN BIOSCIENCE INC (NAGE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NAGE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.